Three- and Four-Dimensional Quantitative Structure Activity Relationship Analyses of Cytochrome P-450 3A4 Inhibitors

Abstract

The program Catalyst was used to build three-dimensional quantitative structure activity relationship (3D-QSAR) pharmacophore models of the structural features common to competitive-type inhibitors of cytochrome P-450 (CYP) 3A4. These were compared with 3D- and four-dimensional (4D)-QSAR partial least-squares (PLS) models built using molecular surface-weighted holistic invariant molecular (MS-WHIM) descriptors for size and shape of the inhibitor. The Catalyst pharmacophore model generated from multiple conformers of competitive inhibitors of CYP3A4-mediated midazolam 1′-hydroxylation (n = 14) yielded a high correlation of observed and predictedKi values of r = 0.91. Similarly, PLS MS-WHIM was used to produce 3D- and 4D-QSARs for this data set and produced models that were statistically predictable after cross-validation. Two additional Catalyst pharmacophores were constructed from literature Ki values (n = 32) derived from the inhibition of CYP3A-mediated cyclosporin A metabolism and IC50 data (n = 22) from the inhibition of CYP3A4-mediated quinine 3-hydroxylation. These Catalyst pharmacophores illustrated correlations of observed and predicted inhibition for CYP3A4 ofr = 0.77 and 0.92, respectively. The corresponding 4D-QSARs generated by PLS MS-WHIM for these data sets were of comparable quality as judged by cross-validation. BothKi pharmacophores generated with Catalyst were also validated by predicting theKi(apparent) values of a test set of eight CYP3A4 inhibitors not included in either model. In seven of eight cases, the residuals of the predictedKi(apparent) values were within 1 log unit of the observed values. The 3D- and 4D-QSAR models produced in this study suggest the utility of future in silico prediction of CYP3A4-mediated drug-drug interactions.

Footnotes

  • Send reprint requests to: Steven A. Wrighton, Ph.D., Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Drop Code 0825, Indianapolis, IN 46285-0001.

  • 1 Present address: Central Research Division, Pfizer Inc., Groton, CT 06340.

  • 2 Present address: Glaxo Wellcome Research and Development, Medicines Research Center, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY United Kingdom.

  • Abbreviations:
    CYP
    cytochrome P-450
    3D
    three-dimensional
    4D
    four-dimensional
    QSAR
    quantitative structure activity relationship
    LOO
    leave one out
    MS-WHIM
    molecular surface-weighted holistic invariant molecular
    PLS
    partial least-squares
    5RG×100
    five random groups repeated up to 100 times
    • Received September 15, 1998.
    • Accepted February 17, 1999.
« Previous | Next Article »Table of Contents